How big is the psoriatic arthritis treatment market?

As of 2027 the market size of psoriatic arthritis treatment is valued at USD 14.07 Billion.

How is the psoriatic arthritis treatment industry projected to perform over the next decade?

Psoriatic Arthritis Treatment Market size was valued at USD 12.94 Billion in 2026 and is anticipated to grow at 10.28% CAGR from 2027 to 2036, surpassing USD 34.43 Billion by 2036.

Why is early diagnosis becoming a key driver of the psoriatic arthritis treatment market?

Improved clinical recognition and diagnostic capabilities are expanding early intervention, increasing demand for therapies that address inflammation, slow disease progression, and support better long-term patient management.

How are research investments shaping treatment strategies for psoriatic arthritis?

Growing R&D investments are advancing biologics and targeted therapies that focus on specific inflammatory pathways, expanding treatment options while supporting more personalized approaches and improved patient outcomes.

Why do injectable therapies dominate the psoriatic arthritis treatment market?

Injectable therapies held a 61.16% market share in 2026 because biologic treatments provide targeted disease control for moderate to severe patients, delivering sustained symptom relief and slowing disease progression.

What is driving the fast growth of disease-modifying antirheumatic drugs (DMARDs)?

DMARDs are the fastest-growing drug type due to their broad role in slowing disease progression, preserving joint function, supporting early intervention strategies, and expanding access to long-term treatment options.

Why does North America lead the psoriatic arthritis treatment market?

North America led in 2026, supported by advanced healthcare infrastructure, specialized rheumatology access, greater disease awareness, and availability of advanced therapeutic approaches.

How is Asia Pacific driving growth in psoriatic arthritis treatments?

Asia Pacific is growing fastest as healthcare access, specialist diagnosis, healthcare investment, and availability of advanced treatments improve across the region.

Who are the major participants shaping the psoriatic arthritis treatment landscape?

Leading companies in the psoriatic arthritis treatment market include AbbVie Inc. (United States), Amgen Inc. (United States), Bristol-Myers Squibb Company (United States), Johnson & Johnson (United States), Pfizer Inc. (United States), Novartis AG (Switzerland), Eli Lilly and Company (United States), UCB S.A. (Belgium), Sanofi (France), Sun Pharmaceutical Industries Ltd. (India)